Long-Term Gene Therapy with Thrombospondin 2 Inhibits TGF-β Activation, Inflammation and Angiogenesis in Chronic Allograft Nephropathy. This evidence concerns the gene TGFB1 and Crouzon syndrome-acanthosis nigricans syndrome.